Global Venous Thromboembolism Treatment Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

The venous thromboembolism treatment market is growing at a significant CAGR due to increase in geriatric population. Rise in the government expenditure, increase in the incidence of venous thromboembolism are fuelling the venous thromboembolism treatment market. Furthermore, increase in surgical procedures such as hip and knee replacements that are risk factors for venous thromboembolism conditions, growing patient awareness venous thromboembolism conditions expected to boost the venous thromboembolism treatment market growth over the forecast period. However, high cost of deep vein thrombosis treatment, high unmet needs of currently available treatment procedures, and adverse effects associated with drugs hinder the growth of venous thromboembolism treatment market. Similarly, stringent regulatory approvals, the presence of alternatives treatments such as thrombectomy and percutaneous techniques are hindering the growth of venous thromboembolism treatment market over the forecast period.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-venous-thromboembolism-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

The venous thromboembolism treatment market is segmented on the basis of drug type, disease type, and distribution channel

Based on drug type, venous thromboembolism treatment market is segmented into the following:
• Factor Xa inhibitors
• Thrombolytic therapy
• Plasminogen activators
• Fondaparinux
• Dabigatran
• Warfarin

Based on disease type, the venous thromboembolism treatment market is segmented into the following:
• Deep vein thrombosis
• Pulmonary embolism

Based on distribution channel, the venous thromboembolism treatment market is segmented into the following:
• Hospital pharmacies
• Online Pharmacies
• Retail pharmacies

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-venous-thromboembolism-treatment-market/#ulp-c654SbFYO64MsOhu

The growth of venous thromboembolism treatment market is due to rise in prevalence of venous thromboembolism (According to the International Society on Thrombosis and Haemostasis, Inc.(ISTH), approximately 10 Mn cases of venous thromboembolism occur annually). The most commonly adopted strategies by industry players include new product launches with technological innovations, new product approvals, acquisitions & mergers, agreements, and collaborations to capture significant venous thromboembolism treatment market share. For instance, in March 2017, The Apex trial reported that extended use of betrixaban beyond the parenteral prophylaxis with enoxaparin reduces the venous thromboembolism incidence among the patients. Similarly, in May 2011, Eliquis (apixaban) approved In Europe for preventing venous thromboembolism after elective knee or hip replacement. Also, in January 2015, Bayer forms the collaboration with academic and governmental institutions for Rivaroxaban study in patients with a recent embolic stroke of undetermined source.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-venous-thromboembolism-treatment-market/#ulp-14mlyhjMGhVjZqa3

Geographically, venous thromboembolism treatment market has been segmented into following regions Viz. North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa. North America anticipated to hold the largest share in the venous thromboembolism treatment market owing to increase in the incidence (According to U.S. International Society on Thrombosis and Haemostasis, Inc. (ISTH) there are around 100,000 to 300,000 venous thromboembolism related deaths reported annually) and prevalence rate, rise in demand for advanced treatments, and increase in aging population in the North America region. Moreover, rise in healthcare expenditure, growing awareness regarding the disease and treatments, and increase in prevalence rate in the Europe region drives the venous thromboembolism treatment market over the forecast period. Asia-Pacific is a key region for venous thromboembolism treatment market due to increase in the government expenditure and healthcare infrastructure. However, high cost of the venous thromboembolism treatment, and low awareness regarding venous thromboembolism treatment among key stakeholders are the key factors hindering the venous thromboembolism treatment market growth in Latin America and Middle East and Africa regions.

Some of the players in venous thromboembolism treatment market are Sanofi (France), Pfizer Inc. (U.S.), Daiichi Sankyo Co. Ltd. (Japan) , Bristol Myers Squibb (U.S.), Johnson & Johnson Services, Inc. (U.S.), AbbVie Inc. (U.S.), Merck & Co. (U.S.), Astellas Pharma Inc. (Japan), Sawai Pharmaceuticals Co. Ltd. (U.S.), Abbott Laboratories (U.S.), Wockhardt Ltd (India), Bayer AG (Germany), and Dupont (U.S.) to name a few.

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-venous-thromboembolism-treatment-market/

"About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs."

"Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: sales@precisionbusinessinsights.com
Toll Free(US): +1-866-598-1553

This release was published on openPR.